TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the 8th Annual Evercore Healthcare Conference, which is taking place from December 2 - 4, 2025.

GlobeNewsWire • Nov 28, 2025

TG Therapeutics: Concerns About Slowing Growth And New Competition

TG Therapeutics continues strong execution with Briumvi, maintaining beat-and-raise performance and robust financials, including a new $100 million buyback program. However, high investor expectations, slowing growth of Briumvi and concerns about increased competition in the multiple sclerosis market have weighted on its share price. Novartis is testing a less frequently administered version of Kesimpta and Roche's fenebrutinib has generated positive phase 3 results in relapsing multiple sclerosis.

Seeking Alpha • Nov 18, 2025

TG Therapeutics: Positives From Q3'25 Earnings, But Competitors Progressing

TGTX has seen rapid enrolment of the ENHANCE study which could allow a simplified dosing regime of IV Briumvi. A readout is possible for mid-2026. Investors may need to wait longer for the subcutaneous formulation of Briumvi to become available, with a readout from clinical work possible in late 2026 or early 2027. Kyverna Therapeutics's KYV-101 is emerging as a potential competitor to TGTX's Azer-cel in Multiple Sclerosis, although initial KYV-101 data is from a handful of patients.

Seeking Alpha • Nov 17, 2025

TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results

Roche presented "unprecedented" test results for its multiple sclerosis treatment, putting pressure on key rival TG Therapeutics.

Investors Business Daily • Nov 10, 2025

Why TG Therapeutics (TGTX) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Nov 5, 2025

TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised

TG Therapeutics beats third-quarter estimates as a surge in Briumvi sales drives revenues up 92.8% and leads to a higher 2025 outlook.

Zacks Investment Research • Nov 4, 2025

Highly Watched TG Therapeutics Smashes Profit Views — With A Caveat

TG Therapeutics stock rose early Monday on better-than-expected third-quarter metrics, including a huge beat on adjusted profit.

Investors Business Daily • Nov 3, 2025

TG Therapeutics, Inc. (TGTX) Q3 2025 Earnings Call Transcript

TG Therapeutics, Inc. ( TGTX ) Q3 2025 Earnings Call November 3, 2025 8:30 AM EST Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Michael Weiss - Chairman, CEO & President Adam Waldman - Chief Commercialization Officer Sean Power - CFO, Corporate Secretary & Treasurer Conference Call Participants Tara Bancroft - TD Cowen, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Corinne Jenkins - Goldman Sachs Group, Inc., Research Division Michael DiFiore - Evercore ISI Institutional Equities, Research Division Emily Bodnar - H.C. Wainwright & Co, LLC, Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division William Wood - B.

Seeking Alpha • Nov 3, 2025

TG Therapeutics Q3 Earnings: Strong Quarter For Briumvi As CD20 Market Grows

TG Therapeutics, Inc. reported strong Q3 results, with Briumvi revenues up 84% year-over-year and full-year guidance raised to $585 million. TGTX continues to expand Briumvi's market presence, driven by clinical data, increased prescriber adoption, and a growing anti-CD20 MS therapy market. A subcutaneous version of Briumvi is in Phase 3 trials, potentially doubling TGTX's market opportunity if approved and launched by 2028.

Seeking Alpha • Nov 3, 2025

TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update

NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, November 3, 2025, at 8:30 AM ET to discuss results for the third quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S.

GlobeNewsWire • Oct 31, 2025